Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Income Before Tax

Profit after all operating and non-operating items but before income tax.

Molecular Partners AGNASDAQ: MOLN

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -CHF 16.77M, compared with -CHF 18.66M a year earlier. Trailing-twelve-month income before tax was -CHF 72.05M.

Context

  • Income before tax increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -CHF 16.77M or moves back toward the trailing-twelve-month quarterly average of -CHF 18.01M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 16.77M-6.0% QoQ
Last fiscal yearDec 2025
-CHF 61.65M-14.1% YoY
LTMMar 2026
-CHF 72.05M-17.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.1%——
1 year-14.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

CHF · from the income statement

Latest · FY2025
(61.65M) CHF
Year-over-year change
-14.1%

Income Before Tax vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.4% is the 7th highest of 9, against a peer median of +9.3%.
MOLN Competitors
Income Before Tax for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$36.23M USD+33.6%—1143.2%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$40.19M USD+21.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$44.76M USD+8.4%—8526.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.55M USD-32.0%—3842.2%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
PEPGPepGen Inc.LTM Mar 2026-$77.15M USD+24.9%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
NKTXNkarta, Inc.LTM Mar 2026-$99.93M USD+10.2%——
ALECAlector, Inc.LTM Mar 2026-$125.22M USD-1.5%—679.9%
Peer median (excluding MOLN) —+9.3%—2492.7%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.33M189.56M7.04M4.97M0
Cost of Revenue55.72M50.75M47.84M47.5M2.58M
Gross Profit(46.39M)138.81M(40.81M)(42.53M)(2.58M)
Gross Margin-497.2%73.2%-579.8%-855.8%—
Research & Development55.72M50.75M48.78M48.6M40.19M
Selling, General & Admin16.91M21.82M19M17.16M14.87M
Operating Expenses72.75M72.94M20.3M18.68M50.89M
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
EBITDA(60.66M)119M(59.52M)(51.65M)(59.49M)
EBITDA Margin-650.2%62.8%-845.6%-1039.2%—
Operating Income(63.42M)116.61M(61.11M)(61.22M)(58.12M)
Operating Margin-679.7%61.5%-868.3%-1231.7%—
Interest Income108.28K1.2M4.28M3.38M1.52M
Interest Expense608.14K648.12K49K25K18K
Other Income / Expenses(365K)1.24M(876K)7.18M(3.53M)
Income Before Tax(63.78M)117.85M(61.98M)(54.04M)(61.65M)
Pre-Tax Margin-683.6%62.2%-880.7%-1087.3%—
Income Tax Expense2K002K2K
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Net Margin-683.7%62.2%-880.7%-1087.4%—
EPS (Basic)(2.06)3.63(1.89)(1.59)(1.65)
EPS (Diluted)(2.06)3.54(1.89)(1.59)(1.65)
Weighted Avg Shares31.01M32.47M32.77M34.03M37.27M
Weighted Avg Shares (Diluted)31.01M33.27M32.77M34.03M37.27M

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.